Board of Directors

Paul Peter Tak, M.D. Ph.D. FMedSci.

Chair of the Board of Directors

Paul Peter Tak received his medical degree cum laude from the Amsterdam University Medical Center (AUMC) and was trained as an internist, rheumatologist and immunologist at Leiden University Medical Center, where he also received his PhD. He has worked as a scientist at the University of California San Diego. Next, he served as Professor of Medicine and founding Chair of the Department of Clinical Immunology and Rheumatology at the AUMC. His scientific work includes pioneering work on the cholinergic anti-inflammatory pathway (inflammatory reflex) in models of chronic inflammation and he led the first clinical trial of vagus nerve stimulation in rheumatoid arthritis. This work has provided a platform from which to explore bioelectronics as a therapeutic approach in autoimmune disease.

He has published extensively in peer-reviewed journals (~600 publications, H-index 142, ranked #120 in the 2023 Edition of the World Ranking of Top 1000 Scientists in the area of Immunology), and served on numerous editorial boards, including as Co-Editor of Arthritis & Rheumatism. He received the Medal of Honour from the Netherlands Society for Rheumatology, was elected ‘Toparts Reumatologie’ (Elected by peers as ‘Best Rheumatologist’ in the Netherlands based on his clinical work making innovative therapies accessible to patients), was awarded Honorary Membership by EULAR and has been elected Fellow of the Academy of Medical Sciences in the U.K. He is a 2021 PharmaVOICE100 honoree (100 most inspiring people in life sciences) and included in ‘The Medicine Maker Power List 2023’ (30 influential and inspirational leaders across small molecule, biopharmaceutical, and cell and gene therapy development and manufacture).

At GlaxoSmithKline he served as Senior Vice President, Chief Immunology Officer, and Global Development Leader. He oversaw the creation of a portfolio of new medicines, including anti-CCL17 antibody, gepotidacin, belimumab sc (approved in 2017 [Benlysta® sc]), mafodotin (approved in 2020 [Blenrep®]), cabotegravir/rilpivirine (approved in 2021 [Cabenuva®]), and tapinarof (acquired by Dermavant Sciences; approved in 2022 [VTAMAR®]). He was the Chair of the Scientific Review Board, the governing body accountable for the scientific assessment of GSK’s R&D portfolio.

He has served as President and CEO of Tempero Pharmaceuticals (acquired by GSK), President and CEO of Kintai Therapeutics (merged with Senda Biosciences), Board Member of Galvani Bioelectronics, ViiV Healthcare, Sitryx Therapeutics (co-founder), Kintai Therapeutics, Omega Therapeutics, and Levicept. He is currently President & CEO of Candel.

Eduardo Bravo

Executive Director

Eduardo has over 25 years of senior management and board experience in the biopharmaceutical sector, having held the position of CEO at Nordic Nanovector, TiGenix and Cellerix. As CEO at TiGenix, he oversaw several financing rounds, the company’s IPO on NASDAQ, and its eventual acquisition by Takeda. Most recently, Eduardo was the CEO of EBAC, an EQT backed SPAC that successfully merged with the clinical stage Swiss biotech Oculis in March 2023.

Earlier in his career, Eduardo held several senior management positions at Sanofi-Aventis and SmithKline Beecham.

He is currently Chairman of the Board at Vivet Therapeutics, Engitix and Ariceum Therapeutics. Eduardo was President of the European Biopharmaceutical Enterprises Board of Directors between 2016 and 2018, and was also member of the Executive Committee of Alliance for Regenerative Medicine. He holds a degree in Business Administration and an MBA from INSEAD. 

Helmuth van Es, Ph.D.

Non-executive Director

Helmuth van Es is co-founder of Citryll and until March 2023 CEO and executive director. He has more than 30 years of experience in the health and life sciences as a scientist and entrepreneur. He has an MSc in Biology/Chemistry and a Ph.D. in Medicine from the University of Amsterdam; his Ph.D. work was on genetic disorders in bilirubin and drug metabolism. Subsequently he was a postdoctoral researcher at Einstein College in New York, and later at McGill University in Montreal, Canada where he worked on drug resistance in malaria. He started his biotech career as a senior scientist at IntroGene, Crucell (now part of J&J). At IntroGene he was responsible for stem cell-based gene therapies for Gaucher disease in partnership with Genzyme. He then co-authored the business plan for Galapagos with former Crucell CEO Ronald Brus to co-found Galapagos. At Galapagos he was Head of Science of the Leiden site under the leadership of CEO Onno van de Stolpe until 2006. He co-developed the strategy of the company that then moved from an adenoviral RNAi technology platform company to a biology driven, drug discovery, development and commercial company. His therapeutic area expertise includes osteoarthritis, rheumatoid arthritis, hearing loss, SLE, Dengue, bacterial infections and cystic fibrosis. As part of the Galapagos team he was responsible for setting up alliances with companies like GSK, Bayer, Incyte and Celgene and the CF foundation. Helmuth is co-inventor of the Galapagos discovery including the groundbreaking industrial application of RNAi.

In 2006 he co-founded a number of companies. Audion Therapeutics BV, is now a pioneering clinical stage, regenerative medicine, small molecule based company focusing on treating acquired hearing loss originally built on intellectual property from Professor Albert Edge (co-founder) at Harvard in Boston. He is co-inventor of LY3056480 a small molecule Notch inhibitor currently in the final stages of phase 2.. He co-founded Effecta Pharma Ltd, discovering antivirals for Dengue and related viruses. He is co-founder and board member of Antabio in France, UK, USA, a company focusing on a new generation of anti-bacterials combatting antibiotic drug resistance. He advised and advises a number of companies including the France, USA, and China based antibody discovery and development company Hifibio. 

Colin Freund

Non-executive Director

Colin Freund is CEO of Modra Pharmaceuticals, and has over 20 years’ experience in the pharmaceutical and biotechnology industries, with a primary focus in oncology. Prior to joining Modra Pharmaceuticals, Colin was Chief Executive Officer, QUE Oncology, Inc., which focused on the development of novel therapies for vasomotor symptoms for patients with breast cancer, and several early-stage anti-cancer therapies. Before QUE, Colin held senior business and corporate development roles at Transgene SA, Agennix Inc., and GPC Biotech AG, all of which focused on developing novel oncology therapeutics. Prior to joining Double Twist, he was a project manager at the Boston Consulting Group, San Francisco, CA, and London, UK, where he managed assignments in the healthcare and high technology practice areas.

Colin received his MA in Economics and Management Studies from the University of Cambridge (UK), and his MBA from Stanford University (USA).

Nora Frey, Ph.D.

Non-executive Director​

Nora brings more than 23 years of professional experience in healthcare research, investment, management and business development. She co-founded several companies and has assumed board- and chairman-ship roles over the years of companies in different sectors including biotech, nutrition and financial/investment.

She studied modern biology and economics in Basel and holds a masters degree in Microbiology and a PhD in Biochemistry in the field of Immunology from the University of Basel.

Nora was part of the BB Biotech management team (Bellevue Group, Switzerland) managing USD 4 bn in public and private biotech investments. Nora then founded Adamant Biomedical Investments AG in Basel, Switzerland, a successful healthcare asset management boutique, managing different healthcare funds. As CIO, she headed research and portfolio management. Among several other awards, Nora was voted finalist in the Ernst&Young Entrepreneur of the Year Award in Switzerland. 

After selling the company to Zürich Cantonal Bank, Nora co-founded Cederberg GmbH, a Swissmedic-registered and regulated company licensing and distributing prescription pharmaceuticals and medical devices.

Nora also has been involved in the project management of several pre-clinical stage molecules. 

In 2019, Nora joined Seventure Partners as venture partner based in Basel.

Daniela Couto, Ph.D.

Non-executive Director

Daniela Couto is a Partner with BGV (BioGeneration Ventures). She joined BGV in 2015 and serves on the board of Catalym, an antibody oncology company.

Daniela served as Managing Director of cardiovascular-focused Staten Biotech, an antibody company that is now collaborating with Novo Nordisk (€ 430 million potential deal). Previously, she was co-founder and CEO at Cell2B, a life sciences company dedicated to treating immune and inflammatory diseases.

Daniela holds a M.Sc. degree with honors in Biomedical Engineering from Universidade do Minho and a PhD degree with the highest honors in Bioengineering from Instituto Superior Técnico (IST) – Technical University of Lisbon and the Massachusetts Institute of Technology (MIT-Portugal Program).

Mariette van der Velden-Roesink


In her first job, Mariëtte van der Velden was responsible for the European product launch and marketing of Cerezyme, one of the first biological orphan drugs. She was inspired by the patient-focus and leadership of the international pioneering company, Genzyme, During the years in business development at Uniqure she was active the international field of gene therapy and viral vaccines and GMP manfacturing services. Through her work as Business Developer at the Amsterdam UMC she helped in the start-up phase of many spin-out companies and became Managing Director for one of the companies. Since 2012 Mariette has built her track record in investments in Dutch life sciences companies. For BOM Capital she realised many investments (25 million euro) and managed a portfolio of up to 13 ventures. In 2018 Mariette decided together with business partner Han de Groot to start and manage a new fund, Curie Capital, to enable promising health care companies to bridge the funding gap in their early development phase, and make an significant impact to improve the health and life of patients.

Floris Hamel, M.Sc.


Floris Hamel is an Investment Manager at BOM, having joined the organization in 2017. Here, he was involved in 20+ deals spread across the Biotech, Medtech and LifeSciences. Currently, Floris manages a broad portfolio, where he holds positions in the board as an observer and shareholder representative. Floris served as board observer for Synaffix, an ADC-technology company recently sold to Lonza.

Throughout his career Floris held other positions as a CRO Business Developer and a Strategic Consultant involved in assignments for start-ups, institutes and clinics across the globe.

Floris holds a B.Sc. degree in Molecular Biology and a M.Sc. degree in Science and Business Management at the University of Utrecht. During these academic endeavors he was involved at Argen-X (NASDAQ:ARG) and Johnson & Johnson (NYSE: JNJ).